EWTX
Edgewise Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$45.32
−3.45%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$46.79
From 52W high−6.27%
Volume1.91M
Market cap$4.92B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$46.79
From 52W high
−6.27%
Volume
1.91M
Market cap
$4.92B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−22.6x
P/E (TTM)
—
RSI (14)
57.3
MomentumView details →
1D Return
−3.45%
YTD Return
+83.76%
SummaryUpdated Jun 1, 2026
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Boulder, Colorado. The company went public in March 2021 and focuses on developing innovative small molecule therapies to treat rare musculoskeletal diseases. Edgewise specializes in precision medicine approaches targeting genetically defined muscle disorders, with their lead drug candidate currently in clinical development for treating devastating muscle-wasting diseases including Duchenne muscular dystrophy.
Similar companies
Latest newsMore news →
Edgewise Therapeutics reported a net loss of $57.3 million for Q2 2026, with R&D expenses of $47.5 million and G&A expenses of $14.4 million.45d agoEdgewise Therapeutics completed the sale of sevasemten and its muscular dystrophy business to Servier for up to $2.65 billion.69d agoEdgewise Therapeutics released topline results from the 12-week Part D cohort of its Phase 2 CIRRUS-HCM trial for a heart drug.96d ago